Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.


Gillespie, SH; Gosling, RD; Uiso, L; Sam, NE; Kanduma, EG; McHugh, TD; (2005) Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. The Journal of antimicrobial chemotherapy, 56 (6). pp. 1169-71. ISSN 0305-7453 DOI: https://doi.org/10.1093/jac/dki376

Full text not available from this repository.

Abstract

Background: In vitro and animal studies have shown that moxifloxacin-containing combinations may improve the bactericidal efficacy of antituberculosis regimens. PATIENTS AND METHODS: We measured the decline in the sputum viable count of 13 patients who were given a combination of moxifloxacin 400 mg daily and isoniazid 300 mg daily. RESULTS: The time required to reduce the viable count by 50% (vt50) was 0.38 days (95% CI -0.03-0.78 days, SEM 0.13) and the mean early bactericidal activity (EBA) was 0.60 log10 cfu/day (95% CI 0.23-0.97, SEM 0.14). This compares with the vt50 calculated for isoniazid and moxifloxacin alone in the same population of 0.48 and 0.88 days, respectively. The EBA values for isoniazid and moxifloxacin alone were 0.77 and 0.53 log10 cfu/day, respectively. CONCLUSIONS: The combination of moxifloxacin and isoniazid is not antagonistic, but the combination does not significantly enhance bactericidal activity above that of isoniazid alone.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Disease Control
PubMed ID: 16223939
Web of Science ID: 233989900034
URI: http://researchonline.lshtm.ac.uk/id/eprint/10302

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
283Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item